LYCIA THERAPEUTICS
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.
LYCIA THERAPEUTICS
Industry:
Biotechnology Health Care Life Science
Founded:
2019-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.lyciatx.com
Total Employee:
11+
Status:
Active
Contact:
(650) 686-8821
Total Funding:
120 M USD
Technology used in webpage:
Microsoft Exchange Online Office 365 Mail
Similar Organizations
54gene
54gene is a healthcare startup that offers a genetics testing platform.
Alphina Therapeutics
Alphina Therapeutics is a biotechnology company that aims to leverage proprietary biomarkers and breakthrough insights for cancer patients.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Blue Lake Biotechnology
Blue Lake Biotechnology is a startup company that focuses on developing a human vaccine using a novel viral vector.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Dyno Therapeutics
Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
Gandeeva Therapeutics
Gandeeva Therapeutics is a precision biotechnology company harnessing the power of cryogenic electron microscopy and machine learning.
Instil Bio
Instil Bio is a biotechnology company that develops cell therapies for solid tumor cures.
Myeloid Therapeutics
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies.
OncoSec Medical
OncoSec is a biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Vera Therapeutics
Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential.
Tulavi Therapeutics
Tulavi Therapeutics is a medical device company that develops products to improve surgical care of peripheral nerve injury.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
XinThera
XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Current Advisors List
Board_member
Board_member
Current Employees Featured
Sarah McWhirter Vice President, Head of Biology @ Lycia Therapeutics
Vice President, Head of Biology
2021-01-01
Steve Staben Chief Scientific Officer @ Lycia Therapeutics
Chief Scientific Officer
2021-10-01
Carolyn Bertozzi Founder @ Lycia Therapeutics
Founder
Aetna Wun Trombley Chief Executive Officer @ Lycia Therapeutics
Chief Executive Officer
2020-04-01
Founder
Investors List
RTW Investments LLC
RTW Investments LLC investment in Series B - Lycia Therapeutics
Eli Lilly
Eli Lilly investment in Series B - Lycia Therapeutics
Redmile Group
Redmile Group investment in Series B - Lycia Therapeutics
Invus
Invus investment in Series B - Lycia Therapeutics
Versant Ventures
Versant Ventures investment in Series B - Lycia Therapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Lycia Therapeutics
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series B - Lycia Therapeutics
Versant Ventures
Versant Ventures investment in Series A - Lycia Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-28 | Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officer |
Official Site Inspections
http://www.lyciatx.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Lycia Therapeutics"
Home - Lycia Therapeutics
Our Science. Our pioneering LYTAC (Lysosomal Targeting Chimera) Platform enables targeted degradation of extracellular proteins. We are utilizing our LYTAC platform to advance a …See details»
About Us - Lycia Therapeutics
We are using our proprietary LYTAC (lysosomal targeting chimeras) Platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins. …See details»
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to ...
Aug 25, 2021 · Under the terms of the agreement, the companies will utilize Lycia’s LYTAC platform to discover and develop novel degraders for up to five targets that aim to address key …See details»
Lycia Therapeutics - Crunchbase Company Profile & Funding
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. Lycia Therapeutics completed a $106.6 million Series C …See details»
Lycia Therapeutics - LinkedIn
Building the leading extracellular protein degradation company | Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at...See details»
Lycia Therapeutics - Overview, News & Similar companies
May 13, 2024 · View Lycia Therapeutics (www.lyciatx.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Versant Ventures Launches Lycia Therapeutics with $50 …
Jun 9, 2020 · SAN FRANCISCO & SAN DIEGO-- ( BUSINESS WIRE )--Biotechnology company Lycia Therapeutics, Inc. today exited stealth mode with a $50 million commitment from founding investor Versant Ventures....See details»
Lycia Therapeutics Strengthens Leadership Team with
Feb 28, 2022 · SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent …See details»
News - Lycia Therapeutics
Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures. Download PDFRead More. August 25, …See details»
Lycia Therapeutics Strengthens Leadership Team with …
Feb 28, 2022 · SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent …See details»
Lycia Therapeutics Completes $106.6 Million Series C Financing to ...
May 13, 2024 · Lycia’s next-generation degradation approach leveraging lysosomal targeting chimeras, or LYTACs, is designed to target the untapped extracellular proteome, including …See details»
Lycia Therapeutics - VentureRadar
Develops a proprietary LYTAC (lysosomal targeting chimeras) Platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins.See details»
Lycia Therapeutics Completes $106.6 Million Series C Financing to ...
SOUTH SAN FRANCISCO, CA, May 13, 2024 – Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the completion of an oversubscribed $106.6 million …See details»
Lycia Therapeutics Announces $70 Million Series B Financing Led …
Sep 9, 2021 · SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the …See details»
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to ...
Aug 25, 2021 · Under the terms of the agreement, the companies will utilize Lycia's LYTAC platform to discover and develop novel degraders for up to five targets that aim to address key …See details»
Lycia Therapeutics Completes $106.6 Million Series C ... - BioSpace
May 13, 2024 · SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the …See details»
Working at Lycia Therapeutics - Glassdoor
Glassdoor gives you an inside look at what it's like to work at Lycia Therapeutics, including salaries, reviews, office photos, and more. This is the Lycia Therapeutics company profile. All …See details»
Lycia Therapeutics Announces $70 Million Series B Financing Led …
Next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The company’s lysosomal targeting chimeras, or …See details»
Lilly and Lycia Therapeutics Enter into Strategic ... - BioSpace
Aug 25, 2021 · Under the terms of the agreement, the companies will utilize Lycia's LYTAC platform to discover and develop novel degraders for up to five targets that aim to address key …See details»
www.lyciatx.org
Www.lyciatx.orgSee details»